Hospira is voluntarily recalling multiple lots of five different injections, due to reports of faulty packaging and contamination.
According to the firm, the recall was took place as the consumers have reported that one lot of preservative-free morphine sulfate injection has experienced problems with a loose crimp or no crimp being applied to the flip top vial, which may result in a potential breach of sterility and contamination of the vial contents.
The contaminated solution could potentially cause thrombosis, phlebitis, bacteremia, sepsis, septic shock, and endocarditis, and critical patient harm may result.
Hospira is also recalling three lots of propofol injectable emulsion, USP, due to visible particles embedded in the glass identified during a retain sample inspection.
The products defect may lead to tissue necrosis in one or more organs, which could result in stroke, myocardial infarction, respiratory failure, and loss of renal and hepatic function.
Hospira also recalled three lots of its diazepam injection, furosemide injection, and Quelicin Succinylcholine Chloride injection, as the customers reported that there was either a loose crimp or no crimp was applied to the flip top vial and in one instance the stopper came out when attempting to remove the flip top cap of the vial.
Hospira said the recalls were being conducted as a precautionary measure and it has not received reports of any adverse events associated with these issues.
The firm said it has notified the US Food and Drug Administration (FDA) about the recall process.
